Wang S, Qi X, Liu D, Xie D, Jiang B, Wang J
Comput Struct Biotechnol J. 2024; 23:491-505.
PMID: 38249783
PMC: 10796827.
DOI: 10.1016/j.csbj.2023.12.016.
Yin J, Cai G, Wang H, Chen W, Liu S, Huang G
Cell Div. 2023; 18(1):9.
PMID: 37301821
PMC: 10257844.
DOI: 10.1186/s13008-023-00091-w.
Chen H, Liu Y, Cao C, Xi H, Chen W, Zheng W
Ann Transl Med. 2021; 9(9):761.
PMID: 34268374
PMC: 8246191.
DOI: 10.21037/atm-19-4511.
Bowden M, Nadal R, Zhou C, Werner L, Barletta J, Juanpere N
Sci Rep. 2020; 10(1):20135.
PMID: 33208770
PMC: 7675970.
DOI: 10.1038/s41598-020-76904-7.
Masood B, Iqbal N, Iqbal W, Masood Y, Akbar M, Mamoon N
Int J Health Sci (Qassim). 2020; 14(2):53-55.
PMID: 32206060
PMC: 7069666.
A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer.
Fan Z, Liang Y, Yang X, Li B, Cui L, Luo L
Onco Targets Ther. 2019; 12:1791-1801.
PMID: 30881032
PMC: 6404681.
DOI: 10.2147/OTT.S186271.
Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.
Cao J, Yin H, Li H, Yu X, Han X
Braz J Med Biol Res. 2017; 50(8):e6207.
PMID: 28746469
PMC: 5520222.
DOI: 10.1590/1414-431X20176207.
[Neuroendocrine carcinoma of the bladder: about 5 cases].
El Bote H, Alaoui A, Oussama Z, El Sayegh H, Iken A, Benslimane L
Pan Afr Med J. 2017; 26:92.
PMID: 28491223
PMC: 5409991.
DOI: 10.11604/pamj.2017.26.92.11488.
[When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?].
Bottke D, Bolenz C, Ott S, Cebulla A, Wiegel T
Urologe A. 2017; 56(5):579-584.
PMID: 28349190
DOI: 10.1007/s00120-017-0356-x.
Rottlerin-induced autophagy leads to apoptosis in bladder cancer cells.
Qi P, He Z, Zhang L, Fan Y, Wang Z
Oncol Lett. 2017; 12(6):4577-4583.
PMID: 28101215
PMC: 5228088.
DOI: 10.3892/ol.2016.5255.
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.
Medioni J, Palma M, Guillot A, Spaeth D, Theodore C
BMC Cancer. 2016; 16:217.
PMID: 26975779
PMC: 4792100.
DOI: 10.1186/s12885-016-2262-9.
Hypofractionated palliative radiotherapy for bladder cancer.
Dirix P, Vingerhoedt S, Joniau S, Van Cleynenbreugel B, Haustermans K
Support Care Cancer. 2015; 24(1):181-186.
PMID: 25975677
DOI: 10.1007/s00520-015-2765-y.
Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
Castellano D, Puente J, de Velasco G, Chirivella I, Lopez-Criado P, Mohedano N
BMC Cancer. 2014; 14:779.
PMID: 25342282
PMC: 4216839.
DOI: 10.1186/1471-2407-14-779.
Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients.
Afonso J, Longatto-Filho A, Moreira da Silva V, Amaro T, Santos L
Oncol Lett. 2014; 8(4):1447-1454.
PMID: 25202348
PMC: 4156165.
DOI: 10.3892/ol.2014.2392.
Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.
Martinez M, Gonzalez I, Tarazona N, Rosello S, Saiz R, Sanmartin A
Clin Transl Oncol. 2014; 17(2):167-72.
PMID: 25100066
DOI: 10.1007/s12094-014-1209-3.
Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment.
Lee J, Kang S, Kim S, Kang S, Choi I, Park Y
Cancer Res Treat. 2014; 46(2):172-7.
PMID: 24851109
PMC: 4022826.
DOI: 10.4143/crt.2014.46.2.172.
Inhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro.
Kang M, Jeong C, Ku J, Kwak C, Kim H
Int J Mol Sci. 2014; 15(5):8106-21.
PMID: 24815071
PMC: 4057722.
DOI: 10.3390/ijms15058106.
Diagnosis of bladder cancer from the voided urine specimens using multi-target fluorescence hybridization.
Ke Z, Lai Y, Ma X, Lil S, Huang W
Oncol Lett. 2014; 7(2):325-330.
PMID: 24396440
PMC: 3881196.
DOI: 10.3892/ol.2013.1744.
Urine telomerase for diagnosis and surveillance of bladder cancer.
Lamarca A, Barriuso J
Adv Urol. 2012; 2012:693631.
PMID: 22888342
PMC: 3410307.
DOI: 10.1155/2012/693631.
